Data and samples collected from people with kidney diseases and healthy controls
Collects health data and samples from adults with kidney diseases and without them.
Key facts
- Who runs it
- The Rogosin Institute
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
- Status
- Recruiting
- People taking part
- 2,000 people, planned
- Started
- Feb 2013
- Expected to end
- Aug 2028
- Type of study
- Observational, 3 groups
- Record updated
- 4 April 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with kidney disease, including diabetes-related, inflammatory or autoimmune kidney disease, or a kidney transplant. People without kidney disease may join as controls.
- Age
- 18 years and older
- Sex
- Men and women
- Disease stage
- Kidney disease, including diabetes with kidney disease, or a kidney transplant that needs a biopsy
Main reasons for not taking part
- Cannot give informed consent
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- All Groups:
- Males or females
- 18 years of age and older
- Willing and able to provide informed consent; Native Biopsy Tissue Group:
- Require an initial kidney biopsy for medical necessity; Native Kidney, Non-tissue Group:
- Previously had a kidney biopsy and the tissue is not stored in this biorepository; or
- Have diabetes and kidney disease and have not had a kidney biopsy; Allograft Tissue Group:
- Have undergone a renal transplant and require a transplant biopsy for either surveillance or "for-cause" indications
Who cannot take part
- Inability to provide informed consent
Where in United States
- The Rogosin InstituteNew York, United StatesContact: Betty-Jane Sloan, M.A.Taking people
About the trial
What the trial wants to find out
A central goal of this data repository is to collect data from a large population of subjects with a variety of renal disease states. Cohorts will include subjects with diabetes, inflammatory/autoimmune and transplant related renal conditions. Additionally, the repository will have the capacity to store biospecimens and electronic data in control subjects without established renal disease. This initiative will provide an opportunity to compare data from various disease states and controls with the objective of determining clinical and biological factors that predict disease progression, response to therapy and identify discriminating noninvasive clinical and biological features that predict renal biopsy findings.
The 3 groups in the trial
- Native, Renal Tissue Preservation Group
Subjects who have a renal biopsy and the tissue is possessed and maintained by the RENAL AID repository.
- Native, Non-tissue Preservation Group
1. Subjects who have had a renal biopsy but the tissue is not held by RENAL AID repository; and/or 2. Subjects with diabetes and renal disease who have not had a renal biopsy.
- Transplant Nephropathy Group
Subjects who have had a renal transplant and require a transplant biopsy for either surveillance or "for-cause" indications.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
- Plain-language title
- Data and samples collected from people with kidney diseases and healthy controlsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 4 April 2025